Fierce Pharma Asia—China's new NRDL; Biocon-Viatris b

Big Pharma's cancer immunotherapies were once again excluded from China's national reimbursement. Biocon and Viatris are reportedly considering combining their biosimilar operations. A Chinese oncology biotech just secured a handsome $200 million series A. And more.

Related Keywords

China , United States , Chinese , American , Brii Bioscience , Eli Lilly , Pfizer , Avistone Pharmaceuticals , Biocon , Syntegon Technology , Spinraza , Escarta Axicabtagene Ciloleucel , Viatris , Shanghai Fosun Pharmaceutical Group , Shanghai Pharmaceutical , Aslan Pharmaceuticals , Iqvia , Drug Reimbursement , Drug Prices , Pd 1 L1 , Immuno Oncology , Biosimilar , M Amp A , Venture Capital , Complete Response Letter , Covid 19 , Antibody Drugs , Drug Approval , Manufacturing , Eczema , Pharma ,